<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021112</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-08981</org_study_id>
    <secondary_id>EORTC-08981</secondary_id>
    <nct_id>NCT00021112</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer</brief_title>
  <official_title>Surgical Treatment Of Stage IIIB Non-Small Cell Lung Cancer After Induction-Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Combining chemotherapy with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation&#xD;
      therapy before surgery in treating patients who have stage IIIB non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the incidence of radically resected disease in patients with stage IIIB&#xD;
           non-small cell lung cancer treated with induction cisplatin, etoposide, and radiotherapy&#xD;
           followed by surgical resection.&#xD;
&#xD;
        -  Determine the toxicity (morbidity and mortality) of this regimen in these patients.&#xD;
&#xD;
        -  Determine the clinical response rate and pathological response rate in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive induction chemotherapy comprising cisplatin IV on day 1 and etoposide IV on&#xD;
      days 1-3. Chemotherapy repeats every 3 weeks for 3 courses. Beginning on day 2 of the second&#xD;
      course of chemotherapy, patients undergo induction radiotherapy once daily 5 days a week for&#xD;
      5-7 weeks. Chemoradiotherapy continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      At 3-6 weeks after completion of the last dose of induction radiotherapy, patients undergo&#xD;
      lobectomy or pneumonectomy.&#xD;
&#xD;
      Patients are followed at 30 days and 4 months, every 6 months for 2 years, and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 27-62 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>April 2001</start_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">5</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed primary stage IIIB non-small cell lung&#xD;
             cancer (NSCLC)&#xD;
&#xD;
               -  T4, any N, M0 or any T, N3, M0&#xD;
&#xD;
               -  No N3 disease due to scalene or supraclavicular lymph node involvement&#xD;
&#xD;
          -  No primary tumors located in the lower lobe combined with contralateral upper higher&#xD;
             mediastinal lymph node involvement&#xD;
&#xD;
          -  No mixed tumor types with small cell lung cancer&#xD;
&#xD;
          -  At least 1 unidimensionally measurable target lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
          -  No pre-existing pleural or pericardial effusion&#xD;
&#xD;
          -  No CNS involvement by CT scan or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm ^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.25 times ULN&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinical evidence of superior vena cava syndrome&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Postoperative FEV1 and KCO greater than 40% predicted&#xD;
&#xD;
          -  VO2 max greater than 15 mL/min/kg (if postoperative KCO no greater than 40% predicted)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other primary malignancy except carcinoma in situ of the cervix, adequately treated&#xD;
             basal cell skin cancer, or other malignancy treated more than 5 years ago without&#xD;
             recurrence (excluding melanoma, breast cancer, or hypernephroma)&#xD;
&#xD;
          -  No active uncontrolled infection requiring IV antibiotics&#xD;
&#xD;
          -  No pre-existing sensory neurotoxicity grade 2 or greater&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior immunotherapy for NSCLC&#xD;
&#xD;
          -  No concurrent immunotherapy during induction chemoradiotherapy&#xD;
&#xD;
          -  Concurrent colony stimulating factors allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for NSCLC&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent anticancer hormonal agents (except corticosteroids for antiemetic&#xD;
             prophylaxis) during induction chemoradiotherapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy for NSCLC&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior surgery for NSCLC&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent anticancer drugs during induction chemoradiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Van Klaveren, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Rotterdam at Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Rohrbach</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen - Lokatie Lukas</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotterdam Cancer Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital - Rotterdam Dijkzigt</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Tuberculosis and Lung Diseases</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

